Development Pipeline
We are engineering a broad pipeline based on clinically validated drug targets that are designed to create a high therapeutic index by maximizing potency while minimizing toxicity.
Janux’s initial development programs are designed to activate T cells within the tumor microenvironment. The company leverages its proprietary tumor activated T cell engager (TRACTr) and its tumor activated immunomodulator (TRACIr) platforms to develop bispecific molecules that once activated are precision engineered to bind to specific tumor antigens and to T cells, thereby focusing T cells to attack the cancer while limiting toxicity elsewhere in the body. Activation of the TRACTrs and TRACIrs within the tumor microenvironment limits toxicity elsewhere in the body.
Program
Targets
Indications
- Discovery Discovery
- IND-Enabling IND-Enabling
- Ph 1 Phase 1
- Ph 2 Phase 2
- Ph 3 Phase 3
WHOLLY OWNED TRACTr PROGRAMS
WHOLLY OWNED TRACIr PROGRAMS
WHOLLY OWNED TRACTr PROGRAMS
Progress
Phase 1
Progress
Phase 1
Progress
Discovery
WHOLLY OWNED TRACIr PROGRAMS
Progress
Discovery